Trials / Completed
CompletedNCT00193063
Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer
Phase II Trial of Weekly Gemcitabine and Herceptin in the Treatment of Patients With HER-2 Overexpressing Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- SCRI Development Innovations, LLC · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Due to its remarkable activity as salvage treatment in women with metastatic breast cancer as well as the additive activity observed for gemcitabine administered in combination with trastuzumab, the clinical activity of the combination of gemcitabine administered with trastuzumab represents an exciting and ideal combination to further evaluate in Her 2 over-expressing metastatic breast cancer patients.
Detailed description
Upon determination of eligibility, all patients will be receive: Gemcitabine + Trastuzumab
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trastuzumab | Trastuzumab |
| DRUG | Gemcitabine | Gemcitabine |
Timeline
- Start date
- 2001-07-01
- Primary completion
- 2009-05-01
- Completion
- 2009-08-01
- First posted
- 2005-09-19
- Last updated
- 2014-03-12
- Results posted
- 2014-03-12
Source: ClinicalTrials.gov record NCT00193063. Inclusion in this directory is not an endorsement.